NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Phase 2

Recruiting

Conditions: Metastatic Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Stage IV Nasopharyngeal Carcinoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2023-06-15

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT05904080

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 78 locations

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Phase 1

Withdrawn

Conditions: Esophageal Neoplasms
Esophagus Neoplasm
Esophagus Cancer
Neoplasms
Neoplasms, Esophageal
Esophageal Cancer (EsC)

Interventions: Drug: Nivolumab
Drug: Entinostat
Biological: Montanide(R) ISA-51 VG Adjuvant
Biological: H1299 Cell Lysates

First Posted Date: 2023-06-12

Last Posted Date: 2024-08-05

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05898828

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Phase 1

Recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Melanoma
Metastatic Merkel Cell Carcinoma
Unresectable Basal Cell Carcinoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Carcinoma in the Skin
Metastatic Basal Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Ipilimumab
Procedure: Kidney Biopsy
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Drug: Prednisone
Drug: Sirolimus

First Posted Date: 2023-06-09

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT05896839

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 23 locations

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia With KMT2A Rearrangement
Acute Myeloid Leukemia With NPM1 Mutation

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Multigated Acquisition Scan
Drug: Revumenib
Procedure: Transthoracic Echocardiography Test

First Posted Date: 2023-06-02

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT05886049

Locations: 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 14 locations

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Nodular Lymphocyte Predominant B-Cell Lymphoma
Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma
Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Biological: Mosunetuzumab
Procedure: Positron Emission Tomography
Biological: Rituximab
Biological: Rituximab and Hyaluronidase Human

First Posted Date: 2023-06-02

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT05886036

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 31 locations

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Phase 1

Not yet recruiting

Conditions: Squamous Non-small Cell Lung Cancer
Lung Cancer
Sinonasal Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Head and Neck Carcnimona

Interventions: Drug: pembrolizumab
Drug: valemetostat

First Posted Date: 2023-05-30

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT05879484

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy

Completed

Conditions: Positive Digital Rectal Examination
Prostate Specific Antigens
Prostatic Neoplasms
Strong Family History of Prostate Cancer

First Posted Date: 2023-05-24

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT05872503

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Phase 2

Recruiting

Conditions: Recurrent Glioma
Recurrent WHO Grade 4 Glioma
Recurrent WHO Grade 2 Glioma
Recurrent WHO Grade 3 Glioma

Interventions: Procedure: Biospecimen Collection
Drug: Erdafitinib
Procedure: Magnetic Resonance Imaging
Procedure: Optical Coherence Tomography

First Posted Date: 2023-05-16

Last Posted Date: 2025-03-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT05859334

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 23 locations

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1

Recruiting

Conditions: Biliary Cancer
Bile Duct Cancer
Cancer of the Bile Duct

Interventions: Drug: oxaliplatin
Drug: capecitabine
Biological: Keytruda
Biological: CDX-1140

First Posted Date: 2023-05-09

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT05849480

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2

Active, not recruiting

Conditions: Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Drug: Docetaxel
Procedure: Echocardiography Test
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Lymphadenectomy
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Procedure: Surgical Procedure

First Posted Date: 2023-05-01

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 240

Registration Number: NCT05836584

Locations: 🇺🇸
Saint Catherine Hospital, Indianapolis, Indiana, United States
🇺🇸
The Community Hospital, Munster, Indiana, United States
🇺🇸
Women's Diagnostic Center - Munster, Munster, Indiana, United States

and more 130 locations

Home Terms & Conditions Privacy Policy